Universitätsklinikum Schleswig-Holstein (UKSH)

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma (2016) Kaehler KC, Hassel JC, Heinzerling L, Loquai C, Moessner R, Ugurel S, Zimmer L, Gutzmer R Journal article Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma (2016) Kirchberger MC, Hauschild A, Schuler G, Heinzerling L Journal article The analysis of heterotaxy patients reveals new loss-of-function variants of GRK5 (2016) Lessel D, Muhammad T, Tena TC, Moepps B, Burkhalter MD, Hitz MP, Toka O, et al. Journal article Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients (2016) Stoehr C, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, et al. Journal article Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases (2016) Klement RJ, Allgaeuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, et al. Journal article Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients (2016) Moinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N, Melchers I, et al. Journal article Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy (2016) Guckenberger M, Klement RJ, Allgaeuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, et al. Journal article High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) (2016) Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Moehle R, Loew S, et al. Journal article Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies (2016) Riemekasten G, Beissert S, Distler J, Kreuter A, Mueller-Ladner U Journal article Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status (2016) Luedeke M, Rinckleb AE, Fitzgerald LM, Geybels MS, Schleutker J, Eeles RA, Teixeira MR, et al. Journal article